Opevesostat for Prostate Cancer
Trial Summary
What is the purpose of this trial?
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS and rPFS per PCWG Modified RECIST 1.1 as assessed by BICR in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.
Will I have to stop taking my current medications?
The trial requires stopping certain medications before participating. You must stop using herbal products with hormonal activity, 5-αreductase inhibitors, and certain other medications like strong CYP3A4 inducers and P-gp inhibitors at least 2-4 weeks before starting the study.
What data supports the effectiveness of the drug Opevesostat for prostate cancer?
Is Opevesostat safe for humans?
What makes the drug Opevesostat for prostate cancer unique?
Opevesostat, combined with Abiraterone acetate and Enzalutamide, offers a novel approach by potentially enhancing the effectiveness of existing prostate cancer treatments. This combination targets different pathways involved in cancer progression, which may improve outcomes compared to using these drugs individually.12589
Research Team
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Eligibility Criteria
This trial is for men with advanced prostate cancer that has spread and resisted treatment, including hormone therapy and up to two chemo treatments. Participants must have a specific performance status, which measures how well they can do daily activities, and cannot have small cell prostate cancer histology.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive opevesostat or alternative NHA until progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Abiraterone acetate
- Dexamethasone
- Enzalutamide
- Fludrocortisone acetate
- Hydrocortisone
- MK-5684
- Prednisone
Abiraterone acetate is already approved in European Union, United States, Canada, Japan for the following indications:
- Metastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer
- High-risk metastatic hormone-sensitive prostate cancer
- Metastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Orion Corporation, Orion Pharma
Industry Sponsor
Liisa Hurme
Orion Corporation, Orion Pharma
Chief Executive Officer since 2022
PhD in Biochemistry, University of Helsinki
Hilpi Rautelin
Orion Corporation, Orion Pharma
Chief Medical Officer since 2023
MD, University of Turku